MENU
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2026 All rights reserved. Tickeron Inc.
ZNTL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Zentalis Pharmaceuticals (ZNTL) Ownership - Who owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more

#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Profile

Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
261.97M
P/E Ratio
N/A
Total Cash
211.76M
Projected Growth
N/A
Total Debt
34.65M
Revenue
N/A
Risk (Beta)
2.41
Dividend Yield
N/A
Total Cash/Share
2.97
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)
Annualized Return+18%
VIEW DETAILSVIEW DETAILS
VIEW FOR FREEVIEW FOR FREE
ZNTL
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
View AI-Driven Trading for ZNTL
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer

Industry Biotechnology

Profile
Details
Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com